Study of TC011 for large B-cell lymphoma that has not responded to treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older
- You must have large B-cell lymphoma that has returned or not improved after at least two previous treatments
- You must have at least one tumor that is 1.5 cm or larger on a scan
- Your heart must pump at least 40% of blood out each beat (measured by LVEF)
- You must be well enough to undergo a procedure called leukapheresis, where white blood cells are collected
- You cannot have had certain prior therapies like CAR T-cell therapy or a stem cell transplant from a donor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This trial tests a new type of immune cell therapy (called AbTCR T-cells) that targets two markers (CD19 and CD22) found on your lymphoma cells. The goal is to see if these modified cells can safely and effectively destroy your cancer when other treatments haven't worked.
This study tests an experimental treatment called TC011, which uses your own immune cells to fight your lymphoma. It is designed for people whose follicular lymphoma has not responded to or has returned after at least two prior treatments.
This study tests a new treatment called CT1190B for people with large B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this treatment can help shrink or control the cancer.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.